ICGC Accelerating Research for Genomic Oncology Data Platform
Accelerating the movement of genomic information into clinical practice
About Our project
Cancer, a disease of the genome, is the leading cause of mortality in Canada, responsible for more than 70,000 deaths per year. While ICGC and PCAWG have been very effective at uncovering the diversity of molecular cancer alterations, finding driver pathways, and illuminating the evolutionary dynamics of tumours, the clinical significance of the phenomena uncovered by ICGC remains mostly unknown. The ICGC-ARGO (Accelerating Research for Genomic Oncology) project is a new phase in the evolution of the ICGC that will more directly impact human health. ICGC-ARGO will produce a far richer and more complex set of genomic, clinical and environmental information than ICGC. This new international collaborative project aims to sequence the tumour and matched normal genomes of 100,000 cancer patients participating in national and international clinical therapeutic trials. This is eight times the number of genomes from the first phase of ICGC, and will include much more complete annotation of high-quality clinical information. Like its predecessor, ICGC-ARGO will have an aggressively open information-sharing policy, with all raw and interpreted genomic and clinical data released to researchers to advance cancer and broader biological discovery.
OICR will build the International Cancer Genome Consortium for Accelerating Research in Genomic Oncology (ICGC-ARGO) Data Coordination Centre (DCC) as well as the Regional Data Processing Centre (RDPC) to collect, analyze, share and interpret sequence and clinical data from 100,000 cancer patients globally. ICGC-ARGO researchers will work across a broad spectrum of disease types, from precancerous lesions and early tumors through to metastases across a broad range of tissue types. Cataloguing the mutational landscape of cancers and linking this data to treatment outcomes will allow us to: identify markers of disease risk, predict response to therapy, predict patterns of drug resistance and develop new targeted therapies.
Our objectives are to:
Implement and operate the ICGC-ARGO Data Coordination Centre (DCC)
Implement a Canadian ICGC-ARGO Regional Data Processing Centre (RDPC)
Implement the ICGC-ARGO Cloud and Data Commons (CDC)
Cataloguing the mutational landscape of cancers and linking this data to treatment outcomes will allow us to: identify markers of disease risk, predict response to therapy, predict patterns of drug resistance and develop new targeted therapies. These insights will allow our clinician partners to provide informed treatment interventions that adapt to a patient’s disease molecular subtype over the course of their disease. Cancer patients in Canada and globally will benefit from improved management of their disease.